Zhonghua bing li xue za zhi Chinese journal of pathology

(ISSN: 0529-5807)

Table of Contents

2017 - 46 (10)

  • [Research progress and application of ROS1 fusion detection in non-small cell lung cancer]. 
  • [Recent progress in application of exosome in diagnosis and treatment of gliomas]. 
  • [Primary ameloblastic carcinoma of maxilla with extensive squamous differentiation areas of dedifferentiation: report of a case]. 
  • [Malignant giant cell tumor of tendon sheath in finger: report of a case]. 
  • [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells]. 
  • [Clinicopathologic characteristics and prognosis of neoplastic cell-rich mixed cellularity classic Hodgkin lymphoma]. 
  • [Clinicopathologic features of three cases of erythropoietic protoporphyria with liver involvement]. 
  • [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application]. 
  • [Poorly-differentiated chordoma with INI1 loss: a clinicopathologic study]. 
  • [Application of ATRX in diagnosis and prognostic evaluation of glioma]. 
  • [miR-449a is a potential epigenetic biomarker for WNT subtype of medulloblastoma]. 
  • [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors]. 
  • [Neuropathologic findings in intractable epilepsy: a clinicopathologic analysis of 822 cases]. 
  • [Infantile Dieulafoy's disease of bronchus: repor/t of a case//]. 
  • [Granuloma faciale: report of a case]. 
  • [Pineal malignant solitary fibrous tumor: report of two cases]. 
  • [Left cervical lymph node enlargement with pain]. 
  • [Detection of fusion gene transcript in formalin-fixed paraffin-embedded myxoid/round cell liposarcoma tissues by improved reverse transcription polymerase chain reaction]. 
  • [Secretory carcinoma of breast: a clinicopathologic analysis of 3 cases]. 
  • [Roles of pathologists in era of precision therapy of cancer: comments on the Food and Drug Administration of the United States approval of pembrolizumab for microsatellite instability-high cancer therapy]. 
  • [Status of PD-L1 testing in non-small cell lung cancer in China]. 
 
 

Journal Information